vs
Side-by-side financial comparison of MANULIFE FINANCIAL CORP (MFC) and Merck & Co. (MRK). Click either name above to swap in a different company.
MANULIFE FINANCIAL CORP is the larger business by last-quarter revenue ($29.4B vs $16.4B, roughly 1.8× Merck & Co.). Merck & Co. runs the higher net margin — 18.1% vs 12.1%, a 6.0% gap on every dollar of revenue.
Manulife Financial Corporation is a Canadian multinational insurance company and financial services provider headquartered in Toronto, Ontario. The company operates in Canada and Asia as "Manulife" and in the United States primarily through its John Hancock Financial division. As of December 2021, the company employed approximately 38,000 people and had 119,000 agents under contract, and has CA$1.4 trillion in assets under management and administration. Manulife at one point serviced over 26 ...
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fourth on the list of largest biomedical companies by revenue.
MFC vs MRK — Head-to-Head
Income Statement — Q3 FY2022 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $29.4B | $16.4B |
| Net Profit | $3.5B | $3.0B |
| Gross Margin | — | 66.2% |
| Operating Margin | — | 20.9% |
| Net Margin | 12.1% | 18.1% |
| Revenue YoY | — | 5.0% |
| Net Profit YoY | — | -20.8% |
| EPS (diluted) | $1.83 | $1.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $16.4B | ||
| Q3 25 | — | $17.3B | ||
| Q2 25 | — | $15.8B | ||
| Q1 25 | — | $15.5B | ||
| Q4 24 | — | $15.6B | ||
| Q3 24 | — | $16.7B | ||
| Q2 24 | — | $16.1B | ||
| Q1 24 | — | $15.8B |
| Q4 25 | — | $3.0B | ||
| Q3 25 | — | $5.8B | ||
| Q2 25 | — | $4.4B | ||
| Q1 25 | — | $5.1B | ||
| Q4 24 | — | $3.7B | ||
| Q3 24 | — | $3.2B | ||
| Q2 24 | — | $5.5B | ||
| Q1 24 | — | $4.8B |
| Q4 25 | — | 66.2% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 77.5% | ||
| Q1 25 | — | 78.0% | ||
| Q4 24 | — | 75.5% | ||
| Q3 24 | — | 75.5% | ||
| Q2 24 | — | 76.8% | ||
| Q1 24 | — | 77.6% |
| Q4 25 | — | 20.9% | ||
| Q3 25 | — | 39.0% | ||
| Q2 25 | — | 31.6% | ||
| Q1 25 | — | 38.0% | ||
| Q4 24 | — | 26.7% | ||
| Q3 24 | — | 24.6% | ||
| Q2 24 | — | 37.3% | ||
| Q1 24 | — | 35.9% |
| Q4 25 | — | 18.1% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | 28.0% | ||
| Q1 25 | — | 32.7% | ||
| Q4 24 | — | 24.0% | ||
| Q3 24 | — | 19.0% | ||
| Q2 24 | — | 33.9% | ||
| Q1 24 | — | 30.2% |
| Q4 25 | — | $1.19 | ||
| Q3 25 | — | $2.32 | ||
| Q2 25 | — | $1.76 | ||
| Q1 25 | — | $2.01 | ||
| Q4 24 | — | $1.49 | ||
| Q3 24 | — | $1.24 | ||
| Q2 24 | — | $2.14 | ||
| Q1 24 | — | $1.87 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $14.6B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $52.6B |
| Total Assets | — | $136.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $14.6B | ||
| Q3 25 | — | $18.2B | ||
| Q2 25 | — | $8.6B | ||
| Q1 25 | — | $9.2B | ||
| Q4 24 | — | $13.7B | ||
| Q3 24 | — | $14.6B | ||
| Q2 24 | — | $11.4B | ||
| Q1 24 | — | $5.6B |
| Q4 25 | — | $52.6B | ||
| Q3 25 | — | $51.9B | ||
| Q2 25 | — | $49.0B | ||
| Q1 25 | — | $48.3B | ||
| Q4 24 | — | $46.3B | ||
| Q3 24 | — | $44.5B | ||
| Q2 24 | — | $43.6B | ||
| Q1 24 | — | $40.4B |
| Q4 25 | — | $136.9B | ||
| Q3 25 | — | $129.5B | ||
| Q2 25 | — | $117.5B | ||
| Q1 25 | — | $115.1B | ||
| Q4 24 | — | $117.1B | ||
| Q3 24 | — | $117.5B | ||
| Q2 24 | — | $112.6B | ||
| Q1 24 | — | $105.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.2K | $2.9B |
| Free Cash FlowOCF − Capex | — | $1.8B |
| FCF MarginFCF / Revenue | — | 11.1% |
| Capex IntensityCapex / Revenue | — | 6.3% |
| Cash ConversionOCF / Net Profit | 0.00× | 0.96× |
| TTM Free Cash FlowTrailing 4 quarters | — | $12.4B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.9B | ||
| Q3 25 | — | $7.8B | ||
| Q2 25 | — | $3.3B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $3.5B | ||
| Q3 24 | — | $9.3B | ||
| Q2 24 | — | $5.6B | ||
| Q1 24 | — | $3.1B |
| Q4 25 | — | $1.8B | ||
| Q3 25 | — | $6.8B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $8.5B | ||
| Q2 24 | — | $4.8B | ||
| Q1 24 | — | $2.2B |
| Q4 25 | — | 11.1% | ||
| Q3 25 | — | 39.6% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 7.5% | ||
| Q4 24 | — | 16.1% | ||
| Q3 24 | — | 51.1% | ||
| Q2 24 | — | 30.1% | ||
| Q1 24 | — | 14.1% |
| Q4 25 | — | 6.3% | ||
| Q3 25 | — | 5.7% | ||
| Q2 25 | — | 4.8% | ||
| Q1 25 | — | 8.6% | ||
| Q4 24 | — | 6.0% | ||
| Q3 24 | — | 4.7% | ||
| Q2 24 | — | 4.9% | ||
| Q1 24 | — | 5.5% |
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 1.35× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.49× | ||
| Q4 24 | — | 0.92× | ||
| Q3 24 | — | 2.94× | ||
| Q2 24 | — | 1.03× | ||
| Q1 24 | — | 0.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MFC
Segment breakdown not available.
MRK
| Pharmaceuticalsegment | $8.7B | 53% |
| Keytruda | $4.9B | 30% |
| Other | $2.7B | 16% |
| Janumet | $57.0M | 0% |
| Isentress Isentress HD | $38.0M | 0% |
| Pifeltro | $25.0M | 0% |
| Belsomra | $23.0M | 0% |
| Dificid | $17.0M | 0% |
| Delstrigo | $14.0M | 0% |
| Lagevrio | $12.0M | 0% |
| Pneumovax23 | $4.0M | 0% |
